SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus

Aberrant activation of the mTOR pathway is a characteristic alteration in triple-negative breast cancer, but the mTOR pathway inhibitor everolimus is not effective for the triple-negative breast cancer (TNBC) patients. Presently, we showed that the activation of ERK pathway was an important mechanis...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Wenwen, Cao, Meiling, Dong, Ke, An, Junhua, Gao, Haidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177683/
https://www.ncbi.nlm.nih.gov/pubmed/37170083
http://dx.doi.org/10.1080/15384047.2023.2206362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177683/
https://www.ncbi.nlm.nih.gov/pubmed/37170083
http://dx.doi.org/10.1080/15384047.2023.2206362

Ejemplares similares